MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy.
Ontology highlight
ABSTRACT: Recently we have shown that the mitogen-activated protein kinase (MAPK) MAPK14/p38α is involved in resistance of colon cancer cells to camptothecin-related drugs. Here we further investigated the cellular mechanisms involved in such drug resistance and showed that, in HCT116 human colorectal adenocarcinoma cells in which TP53 was genetically ablated (HCT116-TP53KO), overexpression of constitutively active MAPK14/p38α decreases cell sensitivity to SN-38 (the active metabolite of irinotecan), inhibits cell proliferation and induces survival-autophagy. Since autophagy is known to facilitate cancer cell resistance to chemotherapy and radiation treatment, we then investigated the relationship between MAPK14/p38α, autophagy and resistance to irinotecan. We demonstrated that induction of autophag
SUBMITTER: Paillas S
PROVIDER: S-EPMC3429546 | biostudies-literature | 2012 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA